Carnosine vs GDF-11 (Growth Differentiation Factor 11)
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Carnosine
Naturally occurring dipeptide (β-alanine + L-histidine) found at high concentrations in skeletal muscle and brain. Functions as a pH buffer, anti-glycation agent, antioxidant, and metal chelator. Extensively studied for athletic performance (pH buffering), neuroprotection, anti-aging (AGE formation prevention), and cataract research (eye drops).
Full profileGDF-11 (Growth Differentiation Factor 11)
TGF-β superfamily member proposed as a 'young blood factor' — circulating GDF-11 declines with age, and young plasma transfusion in parabiosis experiments reversed aging phenotypes in mice. A high-profile but contested research area: some studies show rejuvenating effects in heart, muscle, and brain; others using purified recombinant GDF-11 show cardiac hypertrophy and muscle wasting at pharmacologic doses.
Full profile| Carnosine | GDF-11 (Growth Differentiation Factor 11) | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | β-alanyl-L-histidine, L-carnosine, brain dipeptide, muscle dipeptide | GDF11, Bone Morphogenetic Protein 11, BMP-11, young blood factor |
| Evidence | Research-stage | Research-stage |
| Dosing range | 500mg–2000mg mg, twice daily oral | 0.1mg/kg–1mg/kg mg/kg, every 3–7 days (SC); research protocols vary widely |
| Administration | Oral (capsule/powder), Topical (eye drops — cataract research) | Subcutaneous injection, Intravenous (research) |
| Key side effects | Generally well-tolerated, Mild GI discomfort at high doses (>2g/day), Rare: carnosinemia in carnosinase deficiency (genetic condition), Zinc chelation may reduce zinc availability at very high doses | Cardiac hypertrophy (at pharmacologic doses — the key safety concern), Muscle wasting and weight loss, Reproductive effects (GDF-11 inhibits spermatogenesis and folliculogenesis), Cachexia-like syndrome at high doses |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Carnosine — Oral (capsule/powder), Topical (eye drops — cataract research); GDF-11 (Growth Differentiation Factor 11) — Subcutaneous injection, Intravenous (research).
- Dosing units differ: Carnosine is dosed in mg, GDF-11 (Growth Differentiation Factor 11) in mg/kg — they operate at different scales.
- Frequency: Carnosine is typically twice daily oral; GDF-11 (Growth Differentiation Factor 11) is every 3–7 days (SC); research protocols vary widely.
How each works
Carnosine
Carnosine's multi-mechanism activity explains interest across several research domains. Its histidine moiety buffers intramuscular pH during high-intensity exercise, directly improving performance. As an anti-glycation agent, carnosine quenches reactive carbonyl species that form advanced glycation end-products (AGEs), potentially slowing protein crosslinking associated with tissue aging. Brain carnosine concentrations correlate with cognitive vitality in aging research.
GDF-11 (Growth Differentiation Factor 11)
The 2013–2014 parabiosis studies from Amy Wagers' lab at Harvard proposed GDF-11 as the primary rejuvenating factor in young blood. However, subsequent work by Lee and others showed that purified recombinant GDF-11 at pharmacologic doses caused cardiac hypertrophy, muscle atrophy, and weight loss — opposite of the proposed rejuvenating effects. The field now views GDF-11 as highly dose-sensitive with a narrow therapeutic window, if one exists at all.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.